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The Impact of Inflammation on Metabolomic Profiles
in Patients With Arthritis
Stephen P. Young,1 Sabrina R. Kapoor,2 Mark R. Viant,1 Jonathan J. Byrne,1
Andrew Filer,3 Christopher D. Buckley,2 George D. Kitas,4 and Karim Raza2
Objective. Inflammatory arthritis is associated
with systemic manifestations including alterations in
metabolism. We used nuclear magnetic resonance
(NMR) spectroscopy–based metabolomics to assess
metabolic fingerprints in serum from patients with
established rheumatoid arthritis (RA) and those with
early arthritis.
Methods. Serum samples were collected from
newly presenting patients with established RA who were
naive for disease-modifying antirheumatic drugs,
matched healthy controls, and 2 groups of patients with
synovitis of <3 months’ duration whose outcomes were
determined at clinical followup. Serum metabolomic
profiles were assessed using 1-dimensional 1H-NMR
spectroscopy. Discriminating metabolites were identi-
fied, and the relationships between metabolomic pro-
files and clinical variables including outcomes were
examined.
Results. The serum metabolic fingerprint in es-
tablished RA was clearly distinct from that of healthy
controls. In early arthritis, we were able to stratify the
patients according to the level of current inflammation,
with C-reactive protein correlating with metabolic dif-
ferences in 2 separate groups (P < 0.001). Lactate and
lipids were important discriminators of inflammatory
burden in both early arthritis patient groups. The
sensitivities and specificities of models to predict the
development of either RA or persistent arthritis in
patients with early arthritis were low.
Conclusion. The metabolic fingerprint reflects
inflammatory disease activity in patients with synovitis,
demonstrating that underlying inflammatory processes
drive significant changes in metabolism that can be
measured in the peripheral blood. The identification of
metabolic alterations may provide insights into disease
mechanisms operating in patients with inflammatory
arthritis.
The etiology of rheumatoid arthritis (RA) is not
fully understood but involves both genetic and environ-
mental factors. In addition to synovitis, there are wide-
spread systemic effects mediated by proinflammatory
cytokines that impact on metabolism. Tumor necrosis
factor , interleukin-1 (IL-1), and IL-6 all promote
cachexia, which is often associated with RA (1,2). The
extent of the metabolic changes and the types of metab-
olites seen may therefore be good markers of cytokine-
mediated inflammatory processes in RA. A novel sys-
tems approach to the assessment of metabolic changes in
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disease is metabolomics, which aims to investigate over-
all metabolic activity, and so takes into account the
genetic and environmental background, allowing inte-
gration of the effects of these factors (3). Low serum
levels of a number of specific metabolites, including
histidine, have been reported in RA patients (4), and
this metabolite discriminated osteoarthritis from RA
(5). Lactate levels in synovial fluids also vary, with higher
levels seen in seropositive, than in seronegative, RA (6).
Changes in blood lipids in RA have been widely de-
scribed (7,8). More recently, lipid changes (9) and
alterations in a range of serum cytokines and chemo-
kines (10) have been shown to predate the development
of arthritis, suggesting that changes in metabolites might
be observable early in the development of RA.
Altered metabolic fingerprints have been seen in
a number of inflammatory diseases. For example, ana-
lysis of fecal extracts differentiated between normal
controls, patients with Crohn’s disease, and patients with
ulcerative colitis. Significantly, these two patient groups
could be distinguished using metabolic profiling (11),
suggesting that the effects of inflammation on metabo-
lism vary between conditions. This concept is supported
by our previous work in which we used metabolic
fingerprinting to differentiate between two otherwise
similar inflammatory eye diseases (12) and between a
number of neurologic conditions (13) and also to predict
treatment responses in patients with inflammatory ar-
thritis (14). With this background, we hypothesized that
metabolomic profiles may be useful in predicting the
development of RA in patients with early arthritis, an
area where better predictive tools are currently needed
(15). We also aimed to determine whether this analysis
could provide novel insights into disease mechanisms in
arthritis as has been the case in other conditions (16).
To investigate the potential of metabolic finger-
printing in inflammatory arthritis, we have applied a
nuclear magnetic resonance (NMR)–based metabolo-
mic approach to the analysis of serum from newly
presenting patients with established RA and patients
with early arthritis. We initially sought to assess whether
the metabolic fingerprint in patients with established
RA differed from that of healthy controls and then
whether this fingerprint differed in patients with early
arthritis in relation to the extent of inflammation and
final outcomes.
PATIENTS AND METHODS
Patients. Patients were recruited through the inflam-
matory arthritis clinic at Sandwell and West Birmingham
Hospitals NHS Trust. The study was conducted in compliance
with the Declaration of Helsinki, and ethical approval was
obtained from the local ethics committee. All subjects gave
written informed consent. Serum samples were collected from
the patients and stored at 80°C until analyzed.
Patients with established RA. Serum samples were col-
lected from 16 newly presenting patients who were naive for
disease-modifying antirheumatic drugs (DMARDs), fulfilled
the American College of Rheumatology (ACR) 1987 classifi-
cation criteria for RA (17), and had a symptom duration of3
months. Symptom onset was defined as the time of onset of
inflammatory joint pain and/or early morning stiffness and/or
joint-related soft tissue swelling.
Patients with early arthritis. Serum was collected from
patients with early arthritis at the time of initial presentation.
All patients had one or more swollen joints and symptoms
(inflammatory joint pain, early morning stiffness, and/or joint-
related soft tissue swelling) of 3 months’ duration as previ-
ously described (18). Patients with evidence of previous inflam-
matory joint disease were excluded. Two groups of patients
were studied, one recruited after the other. There were 89
patients with early arthritis in group 1 and 127 in group 2.
Patients were followed up for 18 months and then assigned to
their final diagnostic categories. Patients were classified as
having RA according to the ACR 1987 criteria (17), allowing
criteria to be satisfied cumulatively. Patients were diagnosed as
having reactive arthritis, psoriatic arthritis, and a number of
miscellaneous conditions according to established criteria. As
previously described (18), patients were considered to have
resolving arthritis if they had no evidence of joint-related soft
tissue swelling on final examination and had not received
DMARD or steroid treatment within the previous 3 months.
Persistent disease was defined as persistent joint-related swell-
ing or treatment with DMARDs or steroids for inflammatory
joint symptoms (within the previous 3 months).
Metabolomic analysis. After thawing, serum samples
were centrifuged at high speed (13,000g) and diluted 1:1 with
an aqueous solution containing D2O (20%), NaCl (150 mM),
trimethylsilyl 2,2,3,3-tetradeuteropropionic acid (TMSP) (1
mM), and sodium phosphate (20 mM) (pH 7). One-
dimensional 1H spectra were acquired at 300°K using a stan-
dard spin-echo pulse sequence with water suppression using
excitation sculpting on a Bruker DRX 500 MHz NMR spec-
trometer equipped with a cryoprobe. Spectra for patients with
early arthritis in group 1 and group 2 were acquired several
years apart and so were analyzed separately. Samples were
processed and data were calibrated with respect to the TMSP
signal. Spectra were read into ProMetab (19), custom written
software in MatLab version 7 (The MathWorks), and were
truncated to the chemical shift range of 0.8–10.0 parts per
million. Spectra were segmented into 0.005-ppm (2.5 Hz)
chemical shift “bins” and the spectral area within each bin was
integrated. Spectra were corrected for baseline offset and then
normalized to a total spectral area of unity, and a generalized
log transformation was applied (19,20). Binned data were then
compiled into a matrix, with each row representing an individ-
ual sample.
Statistical analysis. Data bins were mean centered and
subjected to principal components analysis (PCA) using the
PLS_Toolbox (version 5.8) (Eigenvector Research) in MatLab
(release 2009a; MathWorks). Partial least-squares discrimi-
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nant analysis (PLS-DA) was used to perform supervised
clustering of samples (21,22) and on some occasions an
orthogonal signal correction was applied (OPLS-DA) to en-
hance the separation of groups (23). The PLS-DA models were
cross-validated using Venetian blinds (21,22), a method which
reassigns randomly selected blocks of data to the PLS-DA
model to determine the accuracy of the model in correctly
assigning class membership. The application of such methods
to clinical studies has been demonstrated in many studies and
has recently been reviewed by Nicholson et al (24). For all of
the PLS-DA analyses, the variances of Y-block explained by
individual latent variables (LVs) are available from the corre-
sponding author upon request.
Partial least-squares regression analysis (PLS-R), a
regression method that identifies which metabolites can pre-
dict a continuous variable, was also used to investigate the
relationship between the metabolic fingerprint and inflamma-
tory burden, with C-reactive protein (CRP) being used as the
dependent variable. This analysis yields R2, a measure of the
cross-validated goodness-of-fit of the linear regression, while
permutation testing (multiple analyses using random data
subsets) was used to assess the significance of this prediction.
Lists of metabolites providing the greatest discrimina-
tion between groups were then identified for each technique. A
diagram demonstrating the methodologies used is shown in
Supplementary Figure 1, available on the Arthritis & Rheuma-
tism web site at http://onlinelibrary.wiley.com/doi/10.1002/
art.38021/abstract. Using multivariate analyses, peaks with
large loadings (for PCA), weightings (for PLS-DA), or regres-
sion coefficients (for PLS-R) were identified. NMR databases
(Human Metabolome Database version 2.5 [25] and Chenomx
NMR suite; Chenomx, professional version 4.0 [26]) were used
to identify the metabolites. Published data on metabolites
identified in human sera were also used to guide identification
(27,28).
RESULTS
Different metabolomic profiles in patients with
established RA compared to healthy controls. The char-
acteristics of the patients with established RA and age-
and sex-matched healthy controls are shown in Table 1.
The median Disease Activity Score in 28 joints using the
erythrocyte sedimentation rate in the RA patients was
5.88 (interquartile range [IQR] 5.25–6.99). PCA was
used to generate an unbiased overview of the major
metabolic differences between patients with established
RA and control individuals. There was separation of the
2 groups that was largely dependent on principal com-
ponent 2 (Figure 1A), the scores of which were signifi-
cantly higher in the RA group (P  0.0001 by t-test). To
help discover the major discriminatory metabolites,
these data were subjected to supervised analysis using
OPLS-DA. Discriminatory metabolites are shown in
Table 2 (column 1).
Supervised analysis enhanced the separation of
the 2 groups, and the optimized model comprised 4 LVs
that captured 97.8% of the variance in the metabolic
data. The major contributions to the separation were
made by LV1 and LV2 (Figure 1B). This model was
cross-validated using the Venetian blinds approach and
identified samples from the RA patients with a sensitiv-
ity of 93.3% and a specificity of 100%.
Resolution of inflammation is reflected in
metabolomic profile changes. In 22 patients with early
arthritis and active disease at baseline (median CRP 66
Table 1. Baseline characteristics of the patients with established RA, healthy controls, and patients with early arthritis*
Patients with
established RA
(n  16)
Healthy
controls
(n  14)
Patients with early
arthritis in group 1
(n  89)
Patients with early
arthritis in group 2
(n  127) P†
Age, median (IQR) years 57 (37–79) 54 (40–72) 46 (36–61) 50 (35–65) 0.32‡
Sex, no. (%) female 12 (75) 9 (64) 49 (55) 69 (54) 1.0§
Symptom duration, median (IQR) weeks 31 (18–52) – 5 (2–9) 6 (4–9) 0.02‡
No. (%) taking NSAIDs 7 (44) 0 (0) 58 (65) 69 (54) 0.12§
CRP, median (IQR) mg/ml¶ 20.5 (7.5–55.5) – 19 (5.5–54) 19.5 (5.25–44.75) 0.79‡
RF positive, no. (%) 12 (75) – 12 (13) 30 (24) 0.83§
Anti-CCP antibody positive, no. (%)# 9 (56) – 13 (15) 29 (23) 0.39§
No. (%) with persistent arthritis – – 33 (37) 87 (68) 0.0001§
No. (%) with persistent arthritis
who developed RA
– – 18 (54) 55 (63) 0.41§
* RA  rheumatoid arthritis; IQR  interquartile range; NSAIDs  nonsteroidal antiinflammatory drugs; RF  rheumatoid
factor.
† Patients with early arthritis in group 1 versus patients with early arthritis in group 2.
‡ By Mann-Whitney test.
§ By Fisher’s exact test.
¶ Data on C-reactive protein (CRP) were available for 84 patients in group 1 and 126 patients in group 2.
# Data on anti–cyclic citrullinated peptide (anti-CCP) were available for 126 patients in group 2.
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[IQR 47–131]), serum samples were available at a
followup time point (a median of 49 weeks [IQR 24–69]
from the time of initial assessment and sample collec-
tion) at which CRP levels were significantly lower (me-
dian 5 [IQR 5 to 5]). This decrease in CRP was
associated with either spontaneous resolution of disease
or control of disease with therapy. Unbiased PCA
discriminated between samples at baseline and followup
(Figure 1C), and OPLS-DA produced a model compris-
ing 2 LVs that discriminated between these samples with
100% specificity and sensitivity (Figure 1D), demon-
strating the influence of inflammation on the metabolic
fingerprint.
To provide an overall description of which re-
gions discriminated between groups in the PLS-DA
analyses, weightings plots derived from the models were
generated. Some common features were seen in these
weightings plots from PLS-DA models separating RA
patients from controls and in the analysis of the patients
with early synovitis from whom a second serum sample
Figure 1. Metabolic fingerprinting distinguishes between sera from patients with established rheumatoid arthritis (RA) and matched healthy
controls and illustrates that metabolomic profiles in patients with early arthritis are altered by control of or resolution of inflammation. A and B,
One-dimensional 1H–nuclear magnetic resonance (NMR) spectra of serum obtained from disease-modifying antirheumatic drug–naive patients with
RA (solid circles) and healthy controls (open circles) were subjected to principal components analysis (PCA) (A) and to supervised analysis (partial
least-squares discriminant analysis) (B). C and D, One-dimensional 1H-NMR spectra of serum obtained from a subset of patients with early arthritis
before (solid circles) and after (open circles) a decrease in the C-reactive protein level following therapy or spontaneous resolution were subjected
to PCA (C) and to supervised analysis (partial least-squares discriminant analysis with orthogonal signal correction) (D). The values on the axis labels
indicate the proportion of the variance captured by each principal component (PC1 and PC2) or latent variable (LV1 and LV2).
Table 2. Metabolites contributing to the differentiation between groups, determined by analysis of PLS-DA weightings*
Metabolite, ppm
RA patients
versus controls
Patients with early
arthritis before
versus after
resolution of
inflammation
Patients with
persistent arthritis
versus patients
with resolving
arthritis (group 1)
Patients with
persistent arthritis
versus patients
with resolving
arthritis (group 2)
Patients with
persistent RA
versus patients
with resolving
arthritis (group 1)
Patients with
persistent RA
versus patients
with resolving
arthritis (group 2)
LDL-CH3, 0.80 Low (6.30) Low (3.03) Low (6.81) Low (2.87) – –
LDL-CH2, 1.21 Low (7.06) Low (31.81) Low (7.40) Low (6.89) – Low (1.58)
3-hydroxybutyrate,
1.18, 1.19
High (4.21) High (7.90) – High (6.87) – –
Lactate, 1.31, 4.11 High (54.51) – Low (12.85) High (27.90) Low (12.74) High (16.98)
Alanine, 1.46, 1.48 Low (20.00) Low (2.15) – – – Low (3.84)
Acetylglycine, 2.03 High (48.67) High (17.41) High (6.55) High (6.80) High (4.57) Low (1.94)
Methylguanidine,
2.81
Low (10.17) – High (92.72) Low (38.15) High (34.76) Low (6.51)
Taurine, 3.26 High (8.12) High (9.11) – High (15.73) – High (8.66)
Glucose, 3.25, 3.88 High (16.8) High (12.72) – High (11.55) – High (7.49)
Lipid, 5.32 Low (2.36) Low (2.53) – – – –
Urea, 5.79 – High (1.32) High (3.90) – High (1.25) –
*“High” indicates that the metabolite was at a higher concentration in the rheumatoid arthritis (RA; column 2), early arthritis before resolution
(column 3), persistent arthritis (columns 4 and 5), or persistent RA (columns 6 and 7) phenotypes. Nuclear magnetic resonance chemical shifts (in
parts per million), which identify the location of the major peaks in the spectra, are shown for each metabolite. Values in parentheses are the variable
importance of the projection for each metabolite. PLS-DA  partial least-squares discriminant analysis; LDL-CH3  low-density lipoprotein CH3.
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had been collected at a time when the CRP had de-
creased significantly (Table 2 column 2).
Association of metabolomic profiles with inflam-
mation in patients with early arthritis. The characteris-
tics of the 89 patients with early arthritis in group 1 and
the 127 patients with early arthritis in group 2 are shown
in Table 1.
PCA of NMR spectra of serum from 84 patients
with early arthritis (in group 1) in whom the CRP levels
were known showed a broad spread on the scores plot
(Figure 2A). When the CRP level for each sample was
superimposed on the PCA plot, it was clear that the level
of inflammation at the time of sampling influenced the
distribution. To investigate this further, the relationship
between baseline metabolomic profiles and CRP was
assessed using PLS-R. The analysis used a forward
selection approach to discover those NMR bins that
were most predictive. A total of 154 bins created the
optimal model with a cross-validated R2 of 0.671 (Figure
2B). Permutation testing with these 154 NMR bins
demonstrated that the regression model was statistically
valid (P  0.001).
To further validate this relationship between the
level of inflammation and baseline metabolomic pro-
files, the PLS-R analysis was carried out in a separate
group of 127 patients with early arthritis (group 2). The
maximum R2 for the regression of the real (i.e., ordered)
data was 0.416 (Figure 2C). Permutation testing with
1,136 NMR bins included (as optimized by forward
selection) again demonstrated that the regression model
was statistically valid (P  0.001).
It is known that metabolic status and products of
metabolism are influenced by several variables, includ-
ing age, sex, hypertension, diabetes mellitus, hyperurice-
mia, and smoking, but when we adjusted our analysis
for these confounding effects our results remained sig-
nificant (data are available from the corresponding
author upon request). We also excluded the effect of
medication used at the time of sample collection (ste-
roids, DMARDs, and nonsteroidal antiinflammatory
drugs [NSAIDs]) and found that the relationship be-
tween CRP and metabolomic profile was still significant
(data are available from the corresponding author upon
request).
The regression analysis was carried out to exam-
ine the relationship between metabolomic profiles and
CRP without the confounding effect of variables that are
known to influence metabolic status by assessing only
individuals who were not current smokers (n  67 in
group 1 and n  96 in group 2) and individuals without
hypertension (n  70 in group 1 and n  96 in group 2),
diabetes mellitus (n  89 in group 1 and n  118 in
Figure 2. The metabolic fingerprints of sera from patients with early
arthritis prior to treatment with disease-modifying antirheumatic
drugs are strongly influenced by the level of inflammation. A, One-
dimensional 1H-NMR spectra of serum obtained from patients with
very early arthritis (in group 1) were subjected to PCA. Solid circles
indicate C-reactive protein (CRP) levels in the highest tertile, shaded
circles indicate CRP levels in the middle tertile, and open circles
indicate CRP levels in the lowest tertile. B and C, Strong correlations
between measured CRP and predicted CRP values were found for
patients with early arthritis in group 1 (B) and those in group 2 (C)
(P  0.001 for both groups). The predicted values were calculated
from the concentrations of a series of metabolites that were discovered
using partial least-squares regression analysis. Insets show the optimi-
zation of the multivariate regression, with the highest correlation
between measured and predicted CRP occurring with 154 NMR bins
(maximum R2 of 0.671) for group 1 and with 1,136 NMR bins (maximum
R2 of 0.4157) for group 2. See Figure 1 for other definitions.
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group 2), or hyperuricemia (defined as a uric acid level
of 340 moles/liter; n  58 in group 1 and n  67 in
group 2). The effects of DMARDs and steroids on
metabolic status were also excluded by carrying out the
regression analyses only for those patients who were not
taking DMARDs (n  85 in group 1 and n  125 in
group 2; the few patients who were taking DMARDs
were taking them for other comorbidities, e.g., inflam-
matory bowel disease) or steroids (n 86 in group 1 and
n  123 in group 2) at the time of recruitment into the
study. We excluded the effect of NSAIDs by only
carrying out the regression analysis for those patients
who were taking NSAIDs at time of recruitment since
the majority of patients were taking NSAIDs (n  60 in
group 1 and n  66 in group 2). The relationship
between the CRP level and metabolomic profile was
statistically significant for all analyses, except for when
women alone in group 1 were analyzed (data are avail-
able from the corresponding author upon request).
We also used the PLS-R analysis that related the
metabolic fingerprint to CRP level to generate a rank
order of NMR bins that identified the regions of the
spectra that most strongly predicted the inflammatory
burden in groups 1 and 2 (Table 3). Almost identical
groups of metabolites were identified for both patient
groups, suggesting a complex but real relationship be-
tween metabolism and inflammatory burden.
Relationships between clinical outcomes and
metabolomic profiles in patients with early arthritis. A
PLS-DA model was used to attempt to separate patients
with an outcome of resolving arthritis from those with an
outcome of persistent arthritis for both patient groups 1
and 2. The model separated the patients with regard to
outcome but did so with only moderate sensitivity and
specificity, of 59.4% and 58.9%, respectively, for group 1
using 5 LVs (Figure 3A) and 59.5% and 56.4%, respec-
tively, for group 2 using 6 LVs (Figure 3B). There was
also no differentiation between patients with resolving
disease and those with persistent RA in group 1 (Figure
3C) (sensitivity of 50% and specificity of 69.6% using 2
LVs), though there was good separation for group 2
(Figure 3D) with a sensitivity of 73.1% and specificity of
67.6% using 3 LVs.
There was no differentiation between patients
with RA and non-RA outcomes for either cohort (see
Supplementary Figure 2, available on the Arthritis &
Rheumatism web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.38021/abstract). The variances of Y-block
explained by individual LVs are available from the
corresponding author upon request. Previous data have
shown that treatment can affect metabolomic profiles
(29), but there was no significant difference between the
groups with regard to the number of patients taking
NSAIDs (Table 1), and there was no significant differ-
ence in the use of NSAIDs between patients with
persistent disease and those with resolving disease for
group 1 (P  0.13) or group 2 (P  0.1) or between
patients with persistent RA and those with resolving
disease for group 1 (P  0.18) or group 2 (P  0.17).
Metabolites were identified that contributed the
greatest to the separation between patients with early
arthritis with resolving disease and those with persistent
Table 3. Metabolites most strongly correlated with CRP level in patients with early arthritis in groups 1 and 2*
Ranked
importance Metabolites identified in patient group 1 (ppm) Metabolites identified in patient group 2 (ppm)
1 Choline (3.20, 3.22, 3.23) LDL lipids (1.24–1.27)
2 LDL lipids (1.24–1.27) Acetylglycine (2.03, 3.71, 3.76)
3 Lactate (1.31, 1.33, 4.11) Glucose (3.24–3.26, 3.41, 3.48, 3.68–3.69, 3.88)
4 Acetylglycine (2.03, 3.71, 3.76) Fatty acids (0.8–0.84, 2.22–2.24)
5 Urea (5.77, 5.78, 5.79, 5.80, 5.81, 5.82) Methylguanidine (2.81)
6 Glucose (3.24–3.26, 3.41, 3.48, 3.68–3.69, 3.88) Lactate (1.31, 1.33)
7 Methylguanidine (2.81) Threonine (3.58)
8 Methylhistidine (3.70) Homocysteine (3.86)
9 Cholesterol (0.91) Glycine (3.55)
10 Taurine (3.42) Taurine (3.42)
11 Threonine (3.58) Methylxanthine (3.49)
12 Fatty acids (0.8–0.84, 2.22–2.24) Choline (3.20, 3.22, 3.23)
13 Methylxanthine (3.49) Methylhistidine (3.70)
14 Homocysteine (3.86) Cholesterol (0.91)
* Metabolites were identified using the partial least-squares regression analysis model and represent the regions of the
spectra which had the greatest influence on the correlation with C-reactive protein (CRP) level. Values in parentheses
are the nuclear magnetic resonance chemical shifts (in parts per million), which identify the location of the major peaks
in the spectra. LDL  low-density lipoprotein.
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disease, and also between patients with resolving disease
and those with persistent RA for both patient groups
(Table 2). Although some predictive metabolites were
common to both patient groups, there were some key
differences in metabolites between the groups, suggest-
ing that metabolomic techniques as applied in this study
cannot fully discriminate between resolving and persis-
tent outcomes or resolving disease and persistent RA in
patients with early arthritis.
DISCUSSION
Our data demonstrate that the serum metabolic
fingerprint of patients with active established RA differs
from that of healthy controls and that the serum meta-
bolic fingerprint of patients with early arthritis varies
depending on the level of inflammation. These results
from patients with established RA are broadly consistent
with a recent study using a similar experimental ap-
proach that focused on responses to therapy in a cohort
of RA patients (30). There is also some overlap in
discriminating metabolites identified in a recent mass
spectrometry–based analysis of established RA (31).
However, patients in both of those cohorts had already
been exposed to DMARD therapy, and so it is possible
that the therapy might have influenced their metabolic
fingerprints. Our cohort of patients was sampled before
any DMARD therapy and so was not exposed to this
confounding factor.
Consistent with the findings of Lauridsen et al
(30), we found that decreased NMR lipid signals were
particularly discriminatory between different groups.
Madsen et al (31), using mass spectrometry, observed
changes in cholesterol. Such lipid changes were not seen
in a mouse model of arthritis (32), probably because the
investigators filtered samples to remove protein and the
associated lipids. Changes in lipid profiles in the blood
of RA patients have been widely described, and have
been suggested to be a major contributing factor to the
accelerated atherosclerosis associated with RA (7,8).
We found that 3-hydroxybutyrate was elevated in
the patients with established RA compared to controls.
This metabolite is known to be present in RA synovial
fluid (33), in pouch fluid from the rat air-pouch model
(34), and in the blood of mice with experimental arthritis
(32). The presence of 3-hydroxybutyrate, a ketone body,
suggests an increased level of lipolysis in RA patients
compared with controls. This may be another explana-
tion for the decreased levels of lipid that we have
observed, and is consistent with the findings of earlier
spectroscopic studies of synovial fluid (33), which deter-
mined that lipid metabolism may be a predominant
source of energy in the hypoxic inflammatory joint.
Our PLS-R analysis revealed a clear correlation
between the CRP level and the metabolites present. This
was replicated in a separate group of patients. This
approach indicated that increased concentrations of
many of the same metabolites discovered in the PCA
and OPLS-DA models, for example, low-density lipo-
protein lipids, lactate, glucose, taurine, acetylglycine,
and methylguanidine, were predictive of the inflamma-
Figure 3. Metabolic fingerprints of sera from patients with early arthritis from 2 different patient groups. A and B, Serum samples from patients
with early arthritis from group 1 (A) and group 2 (B) at first presentation were assessed using partial least-squares discriminant analysis to distinguish
patients whose disease was resolving (solid circles) from those whose disease was persistent (open circles). Sensitivity and specificity were 59.4% and
58.9%, respectively, for group 1 and 59.5% and 56.4%, respectively, for group 2. C and D, Serum samples from patients with early arthritis from
group 1 (C) and group 2 (D) at first presentation were assessed using partial least-squares discriminant analysis with orthogonal signal correction,
to distinguish patients whose disease was resolving (solid circles) from those who developed persistent RA (open circles). Sensitivity and specificity
were 50% and 69.6%, respectively, for group 1 and 73.1% and 67.6%, respectively, for group 2. See Figure 1 for definitions.
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tory phenotype. However, a number of amino acids
(e.g., choline, threonine, and methylhistidine) were also
found to contribute strongly to the correlation (Table 3).
Thirteen of the 14 metabolites that were most strongly
associated with CRP were the same for both groups of
patients.
Many of the metabolites that were correlated
with inflammation, as measured by serum CRP levels,
are associated with lipid metabolism and may contribute
to the increased levels of atherosclerosis associated with
inflammatory disease. Abnormalities in lipids have been
associated with pre-RA (35), early RA (36,37), and
established RA (38–40), and lipid levels correlate with
CRP even in the absence of clinically apparent inflam-
matory disease (41). Furthermore, lipid-lowering thera-
pies influence inflammation (42,43) and antiinflamma-
tory therapies influence lipids (44), demonstrating a
complex relationship between inflammation and lipid
metabolites which our data help to dissect.
Blood donors who went on to develop RA at least
a decade later have been shown to have significantly
more atherogenic blood lipid profiles than those who did
not develop RA (45). While this difference did not
correlate with CRP levels (45), it does suggest that lipid
profiles early in disease might be predictive of outcome.
However, in the present study we were unable to dis-
criminate between patients with early arthritis who went
on to develop persistent disease and those whose arthri-
tis resolved. Although there was some separation be-
tween patients with persistent disease and those with
resolving outcomes in both groups, the discriminating
metabolites differed. This may result from the hetero-
geneity between the 2 groups of patients with early
arthritis, for example, in terms of the proportion whose
disease persisted (Table 1), and so to confirm and extend
our observations, these analyses need to be replicated in
independent cohorts.
In conclusion, the metabolic fingerprint reflects
inflammatory disease activity in patients with new-onset
arthritis. This suggests that the underlying inflammatory
processes drive significant changes in metabolism that
can be measured in the peripheral blood. This may give
us further insights into the mechanism of inflammation
in inflammatory arthritis, as has been the case following
the identification of contributing metabolites in other
diseases (16). Furthermore, metabolomics may prove
useful as a measure of the extent of disease, potentially
separating patients with low disease activity states from
patients in true remission.
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